

**AMENDMENTS TO THE CLAIMS**

1. (withdrawn) A method of treating a subject in need of modulating the activity of aldose reductase comprising a step of administering the subject with a pharmaceutical dose of fibrate.
2. (withdrawn) The method of claim 1 wherein the fibrate is bezafibrate.
3. (withdrawn) The method of claim 1 wherein the fibrate is selected from the group consisting of clofibrate acid, ciprofibrate, gemfibrozil, fenofibrate.
4. (withdrawn) The method of claim 1 wherein the subject has a condition selected from the group consisting of cardiovascular disease, diabetes, arteriosclerosis, cancer, neoplasm, cataract, retinopathy, keratopathy, nephropathy, neurosis, thrombosis, faulty union of corneal injury and neuropathy.
5. (withdrawn) The method of claim 1 further comprising a step of co-administering the subject with a chemotherapeutics.
6. (currently amended) A method of inhibiting aldose reductase activity in a cell treating a neoplasm comprising a step of contacting said a neoplasm cell with a fibrate.
7. (currently amended) The method of claim 6 wherein the fibrate is bezafibrate[[the]].
8. (currently amended) The method of claim 6 wherein the fibrate is selected from the group consisting of ciprofibrate, gemfibrozil gemfibrizil, and fenofibrate.
9. (currently amended) The method of claim 6 wherein said the cell is a cancer cell-neoplasm is selected from the group consisting of tumor, cancer,

fibromas, melanomas, carcinomas, adenocarcinomas, sarcomas, lymphomas, and leukemias.

10. (currently amended) The method of claim 6 further comprising a step of co-contacting said the cell with a chemotherapeutic[[s]].

11. (withdrawn) A method of modulating the activity of aldose reductase in a cell comprising a step of contacting the cell with fibrate.

12. (withdrawn) The method of claim 11 wherein the fibrate is bezafibrate.

13. (withdrawn) The method of claim 11 wherein the fibrate is selected from the group consisting of clofibrlic acid, ciprofibrate, gemfibrizil, fenofibrate.

14. (new) The method of claim 6, wherein contacting said cell with said fibrate results in an increase in cytotoxicity.